DIFFERENTIAL DEPRESSION OF LYMPHOCYTE SUBSETS ACCORDING TO STAGE IN STOMACH-CANCER

被引：15

作者：

HONG, WS

HONG, SI

KIM, CM

KANG, YK

SONG, JK

LEE, MS

LEE, JO

KANG, TW

机构：

[1] Department of Internal Medicine, Korea Cancer Center Hospital, Nowon-ku, Seoul 139-240, 215-4, Gongneungdong

[2] Department of Clinical Pathology, Korea Cancer Center Hospital, Nowon-ku, Seoul 139-240, 215-4, Gongneungdong

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 1991年 / 21卷 / 02期

关键词：

STOMACH CANCER; LYMPHOCYTE SUBSETS; STAGE;

D O I：

10.1093/oxfordjournals.jjco.a039451

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lymphocyte surface markers were determined in the peripheral blood lymphocytes (PBL) in 31 stomach cancer patients (15 males and 16 females) and 47 controls (20 males and 27 females) using an indirect immunofluorescence technique. The monoclonal antibodies used were Leu 2a (CD8, suppressor/cytotoxic T cells), Leu 3a (CD4, inducer/helper T cells), Leu 4 (CD3, pan T reagent), Leu 11 (CD16, natural killer cells) and Leu 12 (CD19, B cells). The numbers of PBL, CD3+, CD4+, CD8+, CD16+ and CD19+ cells significantly decreased and the CD4:CD8 value increased in patients with stomach cancer compared to those in healthy volunteers. In stage I, PBL, none of the PBL subsets nor the CD4:CD8 value were significantly different from those of the controls. In stage II, the numbers of PBL, CD3+, CD4+ and CD8+ cells decreased. In stage III, the CD19+ cells decreased in addition to the decreased subsets in stage II. In stage IV, PBL and all subsets measured decreased. The CD4:CD8 value showed significant increases in stages II, III and IV, because the CD8+ cells decreased to a greater extent than did the CD4+ cells. Changes in the subsets were analyzed with regard to age, sex, performance status and smoking history, no significant relation being observed between these factors and lymphocyte subsets. From the present study, we have demonstrated that lymphocyte subsets were differentially depressed in the order of T cells, B cells and natural killer cells, with progression of the stage of disease.

引用

页码：87 / 93

页数：7

共 15 条

[1] Wanebo H.J., Prognostic significance of immunologic tests in cancer patients. A review, Surg Clin North Am, 59, pp. 323-347, (1979)
[2] Braun D.P., Harris J.E., Relationship of leukocyte numbers, immunoregulatory cell function, and phytohemagglutinin responsiveness in cancer patients, JNCI, 67, pp. 809-814, (1981)
[3] Kaszubowski P.A., Husby G., Tung K., Williams R., T-lymphocyte subpopulations in peripheral blood and tissues of cancer patients, Cancer Res, 40, pp. 4648-4657, (1980)
[4] Lichtenstein A., Zighelboim J., Dorey F., Brossman S., Fahey J.L., Comparison of immune derangements in patients with different malignancies, Cancer, 45, pp. 2090-2095, (1980)
[5] Saijo N., Shimizu E., Irimajiri N., Ozaki A., Kimura K., Takazawa T., Niitani H., Analysis of natural killer activity and antibody-dependent cellular cytotoxicity in healthy volunteers and in patients with primary lung cancer and metastatic pulmonary tumors, J Cancer Res Clin Oncol, 102, pp. 195-214, (1982)
[6] Dillman R.O., Koziol J.A., Zavanelli M.I., Beauregard J.C., Halliburton B.L., Glassy M.C., Royston I., Immunoincompetence in cancer patients. Assessment by in vitro stimulation tests and quantification of lymphocyte subpopulations, Cancer, 53, pp. 1484-1491, (1984)
[7] Wanebo H.J., Pace R., Hargett S., Katz D., Sando J., Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients, Cancer, 57, pp. 656-662, (1986)
[8] Tsuyuguchi I., Shiratsuchi H., Fukuoka M., Tlymphocyte subsets in primary lung cancer, Jpn J Clin Oncol, 17, pp. 13-17, (1987)
[9] Kim J.-O., Kim S.-Y., Changes of peripheral T lymphocyte subsets following treatment in patients with bronchogenic carcinoma, Korean J Intern Med, 4, pp. 101-107, (1989)
[10] Hong W.-S., Kim C.-M., Lee J.-O., Kang T.-W., Yun T.K., Kim C.-Y., Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy, Jpn J Clin Oncol, 20, pp. 87-93, (1990)

← 1 2 →